報價延遲最少15分鐘:2025/07/09 01:11 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
50.37 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.75/-4.81
|
|
企業價值
4.14B
|
| 資產負債 |
|
每股賬面淨值
13.60
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/09 01:11 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis. |